Merck & Co’s LAVA Therapeutics LVTX Stock Holding History

Merck & Co’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,149,345	Closed	-$1.79M	–	13
2025 Q3	$1.79M	Hold	1,149,345	–	–	0.79%	9
2025 Q2	$1.52M	Hold	1,149,345	–	–	0.7%	8
2025 Q1	$1.46M	Hold	1,149,345	–	–	0.89%	8
2024 Q4	$1.09M	Buy	+1,149,345	New	+$1.8M	0.42%	10

Merck & Co's LVTX Position: Q4 2025 in Review

Merck & Co sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 1,149,345 shares — an estimated $1.79M sold.

Merck & Co first reported a position in LVTX in Q4 2024 and held it in 4 quarters. The position peaked at $1.79M in Q3 2025. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.

Merck & Co reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
Merck & Co sold 1,149,345 LAVA Therapeutics shares in Q4 2025, an estimated $1.79M.
Merck & Co first reported a position in LAVA Therapeutics in Q4 2024 and held it in 4 quarters.
Merck & Co's LAVA Therapeutics position peaked at $1.79M in Q3 2025.
0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.

Based on Merck & Co's 13F filing for Q4 2025, filed 17 Feb 2026.